Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

SIMPLE SUMMARY: There is no clear preference between S-1 and capecitabine in combination with platinum agent as first-line therapy for patients with HER2-negative unresectable advanced or recurrent gastric cancer (GC) with measurable disease. Although a distinguishing use of S-1 versus capecitabine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Hisato, Nishikawa, Kazuhiro, Shimokawa, Toshio, Fujitani, Kazumasa, Tamura, Shigeyuki, Endo, Shunji, Kobayashi, Michiya, Kawada, Junji, Kurokawa, Yukinori, Tsuburaya, Akira, Yoshikawa, Takaki, Sakamoto, Junichi, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688851/
https://www.ncbi.nlm.nih.gov/pubmed/36428770
http://dx.doi.org/10.3390/cancers14225673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688851/
https://www.ncbi.nlm.nih.gov/pubmed/36428770
http://dx.doi.org/10.3390/cancers14225673

Ejemplares similares